Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside?
Explore the exciting world of Vertex Pharmaceuticals (NASDAQ: VRTX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of June 17, 2026. The video was published on Aug. 21, 2026.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $563,135!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $59,383!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $432,189!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
See the 3 stocks »
*Stock Advisor returns as of August 21, 2026.
Anand Chokkavelu has positions in Vertex Pharmaceuticals. Dan Caplinger has no position in any of the stocks mentioned. Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Recommended Articles
